pharmaphorum

APRIL 8, 2022

Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. The Dublin-based pharma is paying $15 million upfront for global rights to Werewolf’s WTX-613, a prodrug of the cytokine interferon alfa-2b, which is still back n preclinical development and due to start its first clinical trials next year.

Immunization 95

Immunization 95

Board Vitals - Pharmacist

APRIL 8, 2022

Funding is something that must be considered when determining your undergraduate and graduate academic goals for nursing school. Nursing school is expensive. Depending on the type of school and nursing program you enroll in, total tuition can range from $6,000 for an associate degree to $100,000 for an advanced degree. Luckily, many organizations offer funding options to nursing students from grants to student loans to scholarships.

Medical Schools 52

Medical Schools 52

pharmaphorum

APRIL 8, 2022

People with psoriasis who used an app developed by digital health company Happify reported reduced anxiety and improvements in mental wellbeing in a real-world study involving more than two hundred subjects. It’s well recognised that people with psoriasis can develop depression or anxiety, particularly in moderate or severe cases where a sizeable part of the body can have skin lesions.

59

59

Pharma Mirror

APRIL 8, 2022

Cambridge, UK, CellCentric, aclinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces the appointments of Kris Frese as Director of Cancer Biology, and Andrew Hughes, who joins the Board as a Non-Executive Director. Both have stellar experience and track records in oncology research and development.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

APRIL 8, 2022

pharmaphorum editor in chief Jonah Comstock takes on the Health Innovators series with a conversation with Amy Bucher, vice president of behavioural design at Lirio and author of “Engaged: Designing for Behavior Change”. Beyond patient engagement and patient activation is the idea of behaviour science and designing for effective behaviour change. Amy has spent her career engaging with these ideas and exploring their applications in the healthcare space.

59

59

Pharma Mirror

APRIL 8, 2022

BARCELONA, Spain and Dundee, UK, a global biopharmaceutical company focused on skin health, today announced a research collaboration with the University of Dundee, a top-ranked university in the UK in biological sciences, to develop a novel approach against chronic and debilitating dermatology diseases where itch, or pruritus, plays a dominant role.

Immunization 52

Immunization 52

Pharma Times

APRIL 8, 2022

Alexion Pharma UK, AstraZeneca’s Rare Disease group, announces the recommendation of its pivotal neurofibromatosis treatment

47

47

pharmaphorum

APRIL 8, 2022

The US Centres for Medicare and Medicaid Services (CMS) has firmed up its draft decision to limit reimbursement of Biogen’s Alzheimer’s disease therapy Aduhelm to a few thousand patients enrolled in clinical trials. The final verdict from the CMS dashes any remaining hopes that Biogen may have held that it would be able to build a market for Aduhelm (aducanumab) in the six million people with Alzheimer’s in the US, many of whom rely on Medicare to reimburse their therapies.

FDA 49

FDA 49

Pharma Times

APRIL 8, 2022

Patients with the life-threatening disease are set to benefit from the Early Access to Medicines Scheme

35

35

pharmaphorum

APRIL 8, 2022

In draft guidance, NICE has said it cannot recommend Gilead Sciences’ Trodelvy in triple-negative breast cancer (TNBC), setting up a disparity in access to the drug via the NHS in the UK. The health technology assessment (HTA) agency said that while Trodelvy (sacituzumab govitecan) increases the time people have before their disease worsens and how long they live, “it is too expensive to be considered a cost-effective use of NHS resources.” While the decision is still open for

Chemotherapy 59

Chemotherapy 59

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA